Therefore, the hyperactivation of the BRAF/MEK/ERK pathway in many cancer types may suppress BIM protein level and evade apoptosis [68], whereas therapies targeting this pathway have been recognized as leading to the accumulation of BIM and induction of apoptosis [45,69,70,71]. The gene discussed is BCL2L11; the disease is cancer.